$2.59 Billion is the total value of Deep Track Capital, LP's 63 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | APOGEE THERAPEUTICS INC | $51,426,145 | – | 2,414,373 | +100.0% | 1.98% | – | |
NVCR | New | NOVOCURE LTD | $40,375,000 | – | 2,500,000 | +100.0% | 1.56% | – |
New | HILLEVAX INC | $39,005,000 | – | 2,900,000 | +100.0% | 1.51% | – | |
NBIX | New | NEUROCRINE BIOSCIENCES INC | $33,750,000 | – | 300,000 | +100.0% | 1.30% | – |
ANAB | New | ANAPTYSBIO INC | $24,170,801 | – | 1,345,813 | +100.0% | 0.93% | – |
OLMA | New | OLEMA PHARMACEUTICALS INC | $23,846,541 | – | 1,930,894 | +100.0% | 0.92% | – |
New | AMYLYX PHARMACEUTICALS INC | $23,058,424 | – | 1,259,335 | +100.0% | 0.89% | – | |
BNTX | New | BIONTECH SEsponsored ads | $21,728,000 | – | 200,000 | +100.0% | 0.84% | – |
MRNA | New | MODERNA INC | $20,658,000 | – | 200,000 | +100.0% | 0.80% | – |
New | ORCHARD THERAPEUTICS PLCspon ads new | $15,782,109 | – | 2,041,670 | +100.0% | 0.61% | – | |
AGIO | New | AGIOS PHARMACEUTICALS INC | $10,450,613 | – | 422,247 | +100.0% | 0.40% | – |
TXG | New | 10X GENOMICS INC | $7,536,004 | – | 182,691 | +100.0% | 0.29% | – |
NVAX | New | NOVAVAX INC | $7,240,000 | – | 1,000,000 | +100.0% | 0.28% | – |
New | ACELYRIN INC | $5,606,609 | – | 551,289 | +100.0% | 0.22% | – | |
New | SYROS PHARMACEUTICALS INC | $3,272,516 | – | 828,485 | +100.0% | 0.13% | – | |
SRRK | New | SCHOLAR ROCK HLDG CORP | $2,512,371 | – | 353,855 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-26 |
SC 13G | 2024-04-26 |
SC 13G/A | 2024-04-22 |
SC 13G | 2024-04-12 |
SC 13G | 2024-04-05 |
SC 13G | 2024-03-22 |
SC 13G | 2024-03-22 |
SC 13G | 2024-03-22 |
SC 13G | 2024-03-15 |
3 | 2024-03-14 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.